| Literature DB >> 29531259 |
Alicia Bort1, Sergio Quesada2, Ágata Ramos-Torres1, Marta Gargantilla2, Eva María Priego2, Sophie Raynal3, Franck Lepifre3, Jose M Gasalla1,4, Nieves Rodriguez-Henche1, Ana Castro5, Inés Díaz-Laviada6,7.
Abstract
The key metabolic sensor adenosine monophosphate-dependent kinase (Entities:
Mesh:
Substances:
Year: 2018 PMID: 29531259 PMCID: PMC5847527 DOI: 10.1038/s41598-018-22690-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1(A) Structures of selected AMPK modulators. (B) Synthetic route followed for the synthesis of final compounds. (C) Structure of the compound 8c.
Figure 2Effect of 2-oxindole fluorinated derivatives on AMPK activity in prostate cancer cells. (A) PC-3, DU145 and LNCaP cells were treated with 25 µM of the selected 2-oxindole fluorinated derivatives for 1 hour. Levels of the phosphorylated AMPK (pAMPK), phosphorylated ACC (pACC) and their total forms were determined by Western blot. Upper panel, a representative Western blot of three different experiments. β-tubulin (β-Tub) serves as a loading control. (B) PC-3, DU145 and LNCaP cells were treated with 25 µM of compound 8c, 25 µM of AMP or 25 µM of A-769662 for 1 hour and processed as above. Lower panels, densitometric analyses of bands represented as the mean of the ratio pAMPK/AMPK or pACC/ACC ± SD of three different experiments. *p < 0.05 compared with the controls by one-way ANOVA followed by Fisher’s LSD test; #p < 0.05 compared with 2-oxindole fluorinated derivates or with the AMPK activators AMP or A769662 by one-way ANOVA followed by Tukey test.
Figure 3Comparison of the effect of 2-oxindole fluorinated derivatives on the proliferation of human prostate cancer cells. (A) Normal (PTN2 and RWPE-1) and cancer (PC3,DU145 and LNCaP) prostate cells were treated with different doses of the compounds for 24 hours and cell viability was monitored by MTT assay. (B) PC-3, DU145 and LNCaP cells were treated with different concentrations compound 8c, AMP or A-769662 for 24 hours, and then viable and total cells were counted. (C) PC-3, DU145 and LNCaP cells were treated with 25 µM of compound 8c for different times. Values were normalized with the control and represent the mean ± SD of at least three independent experiments. *p < 0.05 and **p < 0.01 compared to control by the Student’s - test.
Comparison of inhibitory efficacy of 2-oxindole fluorinated derivatives on human prostate cancer cells viability at 50 μM.
| PTN2 | RWPE-1 | LNCaP | PC-3 | DU145 | |
|---|---|---|---|---|---|
|
| 0 | 17% | 11% | 3% | 14% |
|
| 52% | 42% | 47% | 27% | 14% |
|
| 56% | 50% | 85% | 84% | 88% |
|
| 14% | 8% | 11% | 2% | 16 € |
|
| 8% | 8% | 10% | 23% | 17% |
Figure 4Cell Cycle analysis in 8c-treated prostate cancer cells. (A) PC-3 and LNCaP cells were treated with compound 8c for 24 hours and cell cycle analysis was analyzed by flow cytometry using Propidium Iodide (PI). Percentage of cells in subG0, G1, S, and G2/M phases is indicated in the histogram. (B) Levels of Cyclin D1, p-p53, p53, p21 and cleaved Caspase 3 (17 kDa fragment) were determined by Western blot. Upper panel, representative Western blot of two different experiments. β-tubulin (β-Tub) serves as a loading control. Lower panel, the densitometric analyses of bands represented as the mean ± SD of the two different experiments. *p < 0.05 and **p < 0.01 compared with the control group by the Student’s t-test.
Figure 5AMPK activation by compound 8c in prostate cancer cells. (A) PC-3 and LNCaP cells were treated with vehicle, 25 µM compound 8c, 25 µM compound 8c + 5 μM Dorsomorphin (8c + D) or 5 μM Dorsomorphin (D), for 1 hour or 24 hours and levels of the phosphorylated AMPK (pAMPK), phosphorylated ACC (pACC), phosphorylated Raptor (pRaptor) forms and HIF1α were determined by Western blot. Upper panel, representative Western blot of three different experiments. β-tubulin (β-Tub) serves as a loading control. Lower panel, densitometric analyses of bands represented as the mean of the ratio pAMPK/AMPK or pACC/ACC. (B) Cell viability monitored by MTT assay in PC-3 and LNCaP cells treated with vehicle, 25 µM and 50 μM compound 8c alone or in the presence of 5 μM Dorsomorphin or transfected with control siRNA (siC) or α1AMPK-selective siRNA (siAMPK). (C) LNCaP cells were treated with vehicle, 25 µM compound 8c, 25 µM compound 8c + 5 μM Dorsomorphin (8c + D) or 5 μM Dorsomorphin (D), for 24 hours and levels of Androgen Receptor (AR), Prostate specific antigen (PSA) and Prostate specific membrane antigen (PSMA) were determined by Western blot.Values were normalized with the control and represent the mean ± SD of at least three independent experiments. *p < 0.05 and **p < 0.01 compared to control and #p < 0.05 and ##p < 0.01 compared with 8c-treated group by the Student’s t-test.
Figure 6Phosphorylation of AMPK and ACC in prostate cells transfected with selective AMPKα1 or AMPKα2 siRNA. PC-3 and LNCaP cells were transfected with selective siRNA for AMPKα1 or AMPKα2 subunit isoforms and then treated with vehicle or 25 μM compound 8c for 1 h. Levels of the phosphorylated AMPK (pAMPK), phosphorylated ACC (pACC) and their total forms were determined by Western blot. Upper panel, a representative Western blot of three different experiments. β-tubulin (β-Tub) serves as a loading control. Lower panel, densitometric analyses of bands represented as the mean of the ratio pAMPK/AMPK or pACC/ACC ± SD of three different experiments. *p <0.05 compared with the controls, #p < 0.05 compared with siC by the Student’s t-test. Histogram on the right shows the rate of AMPK α subunit silencing.
Figure 7In vitro activity of human recombinant AMPK. (A) Fluorometric enzymatic assay with the human recombinant AMPK isoform α1β1γ1. This assay evaluated the ability of compound 8c to activate AMPK isoform α1β1γ1and, in turn, phosphorylate the synthetic substrate peptide AMARAASAAALARRR. The compound was evaluated at 30 μM using AMP as a positive control and the Abbott activator A-769662 as positive reference compound. (B) Activity of compound 8c on isolated AMPKα1 1–550 fragment. (C) Co-incubation assay with the human recombinant AMPK isoform α1β1γ1. The compound 8c was evaluated at 30 µM alone or in the presence of different concentrations of A-799662 from 0.3 µM to 30 µM. AMP was used as a positive control for the assay and A-799662 (0.3-3-30 µM) was used as a positive reference compound. Data are the mean ± S.D. of four experiments. **p < 0.01 and ***p < 0.001 compared by the Student’s t-test.
Physicochemical descriptors of compound 8c calculated by QikProp 3.5 integrated in Maestro (Schrödinger, LLC, New York, USA).
| Descriptor | Compound 8 c |
|---|---|
|
| −4,961 |
|
| 3041,015 |
|
| 2307,16 |
| 100 |
aPredicted aqueous solubility [-6.5/0.5]; bApparent Caco-2 cell permeability in nm/s [<25 poor, >500 excellent]; cApparent MDCK permeability in nm/s [<25 poor, >500 excellent] dHuman Oral Absorption in GI [<25% is poor]; [range of 95% of drugs].
Figure 8Inhibition of prostate tumor xenograft growth in vivo by compound 8c. (A) Growth curves of xenograft PC-3 tumors in mice daily treated with vehicle (Control), or 5 mg/Kg compound 8c. Results are the mean (n = 8) ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.005 compared to controls by the Student’s t test. (B) Pictures of representative athymic nude mice bearing PC-3 cell tumor xenografts and the dissected tumors. (C) levels of phospho-AMPK, phospho-ACC, Cyclin D1 and proCaspase-3, in 4 representative control mice and 4 representative 8c-treated mice. β-tubulin serves as a loading control. (D) The densitometric analyses of bands represented as the mean (n = 8) ± S.D. *p < 0.05 compared with the control group by the Student’s t-test.